The 3.6mm docking button is designed to allow the Nanostim device to be retrieved after implantation.
Abbott Laboratories (NYSE:ABT) said this month that it’s maintaining the worldwide halt on implantations of the Nanostim leadless pacemaker made by its St. Jude Medical subsidiary after reports surfaced of problems with the device’s docking button.
The 3.6mm docking button is designed to allow the Nanostim device to be retrieved after implantation; it’s meant to connect with the retrieval catheter during removal. In a Nov. 17 letter to physicians, Abbott said it received three reports of docking buttons detaching, out of 1,423 Nanostim implantations (0.002%), with no serious injuries reported.
